Autem Therapeutics

Autem Therapeutics is a Hanover, New Hampshire bioelectric oncology company developing AutEMsys, a non-invasive, non-toxic device that delivers personalized, low-level, amplitude-modulated electromagnetic frequencies to patients with solid tumors. Founded by medical oncologist Frederico Costa and led by CEO Michael Choukas, the company targets hepatocellular carcinoma (liver cancer) and other hard-to-treat cancers, aiming to make effective cancer care portable, affordable, and accessible worldwide. Its lead program has earned FDA Breakthrough Device designation for advanced HCC.